In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous ...

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma and is curable in more than 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

Who can vote in a primary election? New York’s primaries are closed primaries. To vote in a political party’s primary election, you need to be registered as a member of that party.

June 14: Last day to register in-person or online to vote in the primary. Mailed applications must be received by this date, so get them in the mail a few days earlier. June 14-22: Early voting.

At the second attempt, the FDA has approved Citius Pharmaceuticals' Lymphir for rare lymphoma CTCL. Skip to main content Monday 23 June 2025 . BlueSky linkedin youtube rss. User account menu ...